Watson to Present at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top

PARSIPPANY, N.J., Dec. 22, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Thursday, January 5, 2012 at 1:45 pm Eastern Time at the Goldman Sachs Conference Center in New York, New York. The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Website at http://ir.watson.com.  The webcast can also be accessed at the following URL:

http://cc.talkpoint.com/gold006/010512a_lr/?entity=1_2C46T3C

An archived version will be available within two hours after the live presentation ends and can be accessed at the same locations for 30 days.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

 

CONTACTS:

Investors:

 

Patty Eisenhaur

 

(862) 261-8141

 

 

 

Media:

 

Charlie Mayr

 

(862) 261-8030

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

SOURCE Watson Pharmaceuticals, Inc.

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

With a green light in lung cancer, AstraZeneca's Imfinzi has become the first PD-L1 drug approved in China, ahead of Roche's Tecentriq.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.